Quick answer
What have the retatrutide phase 3 trials published? As of 17 November 2026, TRIUMPH-1 reported mean body weight changes of -17.6% to -25.0% at 80 weeks versus -3.9% with placebo, and TRIUMPH-2 reported -11.9% to -18.8% versus -5.1% in adults with type 2 diabetes. Gastrointestinal events were the most common adverse events. This summarizes abstracts and registry records only; V8 retatrutide is a laboratory research reagent.
By late 2026 the retatrutide literature has moved from phase 2 to phase 3, and the first full publications of the TRIUMPH program are out. For a laboratory that uses retatrutide as a reference material, those papers are context: they define what the molecule is understood to do at the whole-organism level in people, and they shape the questions the field asks next. This article summarizes what the primary publications and the ClinicalTrials.gov registry state as of 17 November 2026, tells apart what each one does and does not show, and lists what a bench scientist should and should not take from them. It is a literature summary. It does not describe any use of a laboratory material outside the laboratory, and nothing in it is advice of any kind.
Background on the molecule is on the retatrutide product page: a 39-residue synthetic peptide agonist of the GIP, GLP-1 and glucagon receptors, supplied as lyophilized powder for laboratory research use only. For earlier evidence see the retatrutide research overview.
How to read a phase 3 abstract without over-reading it
Three terms recur in the 2026 papers and are worth defining. An estimand is the precise quantity a trial tries to estimate. The papers report a "exposure-regimen" or "intention-to-handle" (ITT) estimand, which counts everyone as randomized regardless of what they did afterward, and a "hybrid" estimand for pain and sleep end points, which handles participants whose course suggests exposure failure with a hypothetical strategy. Both appear side by side in the abstracts, and they differ in magnitude. A percentage-point difference against placebo is not the same as the raw percent change in the active group, because placebo groups also change. And a primary end point is the pre-specified outcome; anything else is secondary and should be read with that status in mind.
Step one: the earlier phase 2 and phase 1 record
Phase 3 stands on earlier work. The molecule was first described with rodent pharmacology and a single-ascending-dose phase 1 study (Coskun et al., 2022). The phase 2 obesity trial enrolled 338 adults and reported least-squares mean changes in body weight at 24 weeks of -7.2% with the 1 mg group up to -17.5% with the 12 mg group, against -1.6% with placebo (Jastreboff et al., 2023). The phase 2 trial in type 2 diabetes was published in The Lancet (Rosenstock et al., 2023), and a liver-fat substudy reported reductions of up to 82.4% in mean relative liver fat at 24 weeks in participants with metabolic dysfunction-associated steatotic liver disease (Sanyal et al., 2024). Those papers are why the phase 3 program was designed the way it was: obesity as the central population, with type 2 diabetes and organ-specific baskets nested alongside.
Step two: the TRIUMPH-1 publication
The TRIUMPH-1 publication in the New England Journal of Medicine (Jastreboff et al., 2026) reports a randomized, double-blind phase 3 trial in adults with obesity without diabetes, comparing three retatrutide arms (4, 9 and 12 mg once weekly) with placebo for 80 weeks. Participants numbered 2,339 at randomization. Mean percent change in body weight was -17.6%, -23.7% and -25.0% across the three arms against -3.9% with placebo, a difference from placebo of -19.8 and -21.0 percentage points for the 9 and 12 mg arms (P<0.001). The paper also reports two sub-populations with their own primary end points. In the subgroup with knee osteoarthritis (574 participants), the change in WOMAC pain score under the hybrid estimand was -3.2, -3.5 and -3.6 versus -1.9 with placebo; in the subgroup with obstructive sleep apnea (243 participants), the change in apnea-hypopnea events per hour was -22.9, -34.3 and -31.7 versus -9.9. The abstract states that the most common adverse events were gastrointestinal, that the trial was funded by Eli Lilly and that it is registered as NCT05929066.
Step three: the TRIUMPH-2 publication in type 2 diabetes
TRIUMPH-2, published in The Lancet in October 2026, enrolled 1,152 adults with a body mass index of at least 27 and type 2 diabetes at 92 centres in eight countries, randomizing them to 4, 9 or 12 mg of retatrutide or placebo (Bellido et al., 2026). For the exposure-regimen estimand, the mean change in body weight at week 80 was -11.9%, -16.8% and -18.8% across the three arms, against -5.1% with placebo; the estimated differences from placebo were -6.9, -11.8 and -13.8 percentage points. Gastrointestinal events were the most frequently reported, and the abstract gives specific frequencies: diarrhoea in 27%, 34% and 34% of the three arms versus 13% with placebo, and nausea in 14%, 21% and 28% versus 8%. Hypotension and dysesthesia were also more frequent than with placebo. Permanent exposure discontinuation due to adverse events or death was reported for 4% (4 mg), 12% (9 mg), 8% (12 mg) and 5% (placebo), and the abstract reports that the investigators deemed all deaths unrelated to the study intervention. A Lancet commentary on TRIUMPH-2 also appeared in the same month (Holst, 2026).
| Trial | Population | Duration | Weight change, highest-dose arm | Placebo | Source |
|---|---|---|---|---|---|
| TRIUMPH-1 | Adults with obesity, no diabetes (n=2,339) | 80 weeks | -25.0% (12 mg) | -3.9% | Jastreboff et al., 2026 |
| TRIUMPH-2 | Adults with obesity and type 2 diabetes (n=1,152) | 80 weeks | -18.8% (12 mg) | -5.1% | Bellido et al., 2026 |
| TRIUMPH-4 | Obesity with painful knee osteoarthritis (n=445) | 68 weeks | -23.7% (12 mg) | -4.6% | Schnitzer et al., 2026 |
| Phase 2 obesity | Adults with obesity (n=338) | 48 weeks (primary end point at 24 weeks) | -17.5% at 24 weeks (12 mg) | -1.6% at 24 weeks | Jastreboff et al., 2023 |
The numbers are not directly comparable across rows because populations, durations, estimands and baseline characteristics differ. The table is an index to the papers, not a ranking.
Step four: knee osteoarthritis and sleep apnea publications
The New England Journal of Medicine published a paper on knee osteoarthritis pain combining TRIUMPH-4 and TRIUMPH-1-OA (Schnitzer et al., 2026). TRIUMPH-4 randomized 445 adults without diabetes who had painful knee osteoarthritis and a body mass index of at least 27 to retatrutide 9 or 12 mg or placebo, with end points of WOMAC pain score and percent change in body weight at week 68. The WOMAC difference from placebo under the hybrid estimand was -1.83 for 9 mg and -1.61 for 12 mg, and percent change in body weight was -20.0% and -23.7% versus -4.6% with placebo. The abstract notes that serious adverse events were more common with retatrutide than with placebo and that the most common adverse events were gastrointestinal. A separate New England Journal of Medicine paper reports two phase 3 sleep apnea trials nested within the larger basket program (Grunstein et al., 2026); in TRIUMPH-1-OSA the apnea-hypopnea index changes under the hybrid estimand were -22.9, -34.3 and -31.7 events per hour versus -9.9 with placebo.
What the ClinicalTrials.gov registry shows
Registered trials are a useful map of what is still unreported. A query of ClinicalTrials.gov on 17 November 2026 for retatrutide returned a program that spans phase 1 pharmacology studies through phase 3. The table lists a selection of phase 3 entries as registered, with the status and the primary completion date field of the record; where a date is in the future it is a projection by the sponsor, not an observed fact, and statuses change.
| Registry ID | Name or topic | Status in registry | Primary completion (registry field) | Enrollment (registry) |
|---|---|---|---|---|
| NCT05929066 | TRIUMPH-1: obesity or overweight | Completed | 2026-04-06 | 2,335 |
| NCT05929079 | TRIUMPH-2: type 2 diabetes | Completed | 2026-06-16 | 1,152 |
| NCT05882045 | TRIUMPH-3: obesity and cardiovascular disease | Completed | 2026-04-16 | 1,946 |
| NCT05931367 | TRIUMPH-4: obesity with knee osteoarthritis | Completed | 2025-11-14 | 445 |
| NCT06662383 | TRIUMPH-5: comparison with tirzepatide | Active, not recruiting | 2026-11 | 800 |
| NCT06859268 | TRIUMPH-6: weight-reduction maintenance | Active, not recruiting | 2028-04 | 643 |
| NCT07035093 | TRIUMPH-7: obesity and chronic low back pain | Active, not recruiting | 2027-09 | 586 |
| NCT06383390 | Cardiovascular and kidney outcomes | Active, not recruiting | 2029-02 | 10,000 |
The registry also lists a pre-approval expanded access record. This article takes no position on it. The reader is directed to the record itself on ClinicalTrials.gov.
Two practical points follow. First, only a subset of the completed trials has a full peer-reviewed publication in the sources checked for this article; absence of a publication here does not mean absence of data elsewhere. Second, the registry records are updated by sponsors, so a laboratory citing the program should record the date of access, as this article does.
What the phase 3 literature means for a laboratory
A bench scientist can take four things from the publications without extending them beyond what they show. First, the molecule is a validated reference for triple-receptor incretin pharmacology: its behaviour has now been characterized in thousands of people, which gives assay results a point of comparison. Second, the adverse-event profile reported in the abstracts is dominated by gastrointestinal events, consistent with the incretin class, a fact worth knowing when interpreting gut-related readouts in preclinical models. Third, the papers establish that benefits and risks were measured under supervised trial conditions with a specific formulation, and none of that transfers to laboratory-grade lyophilized powder; the V8 material is not the trial formulation and is not for any use outside a laboratory. Fourth, the trials do not answer mechanism questions. The partition of effects among the three receptors is a preclinical question; see the research overview.
For how retatrutide compares with other incretin agonists, see retatrutide vs tirzepatide and the 2026 incretin comparison. Handling guidance is in retatrutide reconstitution and handling. Quality documentation for the V8 material is on the COA page, with analytic principles in retatrutide purity testing. The catalogue is on the shop page.
Limits of this summary
The author read the abstracts and registry records, not the full papers. Statements about design, numbers and adverse events come from those abstracts, and nothing here goes beyond them. Where an abstract truncates or omits detail, such as the full adverse-event tables of the larger trials, this article does not supply it. Readers who need detail should consult the full texts through the DOIs in the reference list.
Frequently asked questions
What is the TRIUMPH program?
The phase 3 clinical program for retatrutide, sponsored by Eli Lilly, with trials in obesity, type 2 diabetes, cardiovascular disease, knee osteoarthritis, sleep apnea and other settings. Details are in the ClinicalTrials.gov registry.
What did TRIUMPH-1 report?
At 80 weeks, mean percent change in body weight was -17.6%, -23.7% and -25.0% across three retatrutide arms versus -3.9% with placebo in 2,339 randomized adults with obesity (Jastreboff et al., 2026).
What did TRIUMPH-2 report?
In 1,152 adults with obesity and type 2 diabetes, mean weight change at week 80 was -11.9%, -16.8% and -18.8% across arms versus -5.1% with placebo, with gastrointestinal events most common (Bellido et al., 2026).
Are the results comparable across trials?
Not directly. Populations, durations, estimands and baselines differ, so each result should be read within its own trial.
What is a hybrid estimand?
An analysis strategy used for some end points that handles participants whose course suggests exposure failure with a hypothetical strategy and handles other events as they occurred. Papers usually also report an ITT analysis (all participants as randomized).
Where is the registry information from?
ClinicalTrials.gov, queried on 17 November 2026. Dates in the future are sponsor projections and statuses change.
Do these trials tell me about the V8 research material?
No. They used a clinical formulation under supervision. V8 retatrutide is a laboratory research reagent, and the trials say nothing about its use outside the laboratory.
Do the trials explain how retatrutide works?
They report outcomes, not mechanism. Receptor-level mechanism comes from preclinical work and is covered in a separate article on energy balance.
What adverse events did the abstracts mention most?
Gastrointestinal events were the most common in the cited abstracts, and serious adverse events were more common with retatrutide than placebo in the knee osteoarthritis paper.
Is retatrutide approved?
This article does not make regulatory statements. V8 supplies retatrutide strictly for laboratory research use only; the registry lists the clinical program and an expanded-access record.
Related reading: Retatrutide Guide: Chemistry to Phase 3 Evidence, Retatrutide Side Effects: What Preclinical Studies Report, Retatrutide and Fat Loss: Intake vs Expenditure.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. doi:10.1016/j.cmet.2022.07.013
- Jastreboff AM, et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med. 2026. doi:10.1056/NEJMoa2604169
- Bellido D, le Roux CW, Ekinci E, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;408(10563):1455-1472. doi:10.1016/S0140-6736(26)01861-1
- Holst JJ. Retatrutide in adults with obesity and type 2 diabetes: what have we learned from TRIUMPH-2? Lancet. 2026;408:1398-1399. doi:10.1016/S0140-6736(26)01987-2
- Schnitzer T, Hunter DJ, Conaghan PG, et al. Retatrutide once weekly in adults with knee osteoarthritis pain and obesity. N Engl J Med. 2026. doi:10.1056/NEJMoa2610676
- Grunstein R, et al. Retatrutide once weekly for treatment of obstructive sleep apnea. N Engl J Med. 2026. doi:10.1056/NEJMoa2611477
- ClinicalTrials.gov. Retatrutide intervention search. U.S. National Library of Medicine. Accessed 17 November 2026. https://clinicaltrials.gov
